Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2009-02-21

AUTHORS

Riki Okita, Mamoru Takahashi, Hiroyuki Narahara, Yuichi Sanada, Morihito Okada, Yoshiiku Kawakami, Kazuaki Chayama, Kiwamu Okita

ABSTRACT

Reactivation of hepatitis B virus (HBV) infection is a frequent complication of cytotoxic chemotherapy that includes steroids. International studies have shown that lamivudine reduces the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy to treat malignancies. However, prolonged lamivudine therapy is associated with an increased risk of drug-resistant tyrosine-methionine-aspartate-aspartate (YMDD) mutations. Here, we studied the role of entecavir in preventing morbidity and mortality associated with HBV reactivation. Three patients with both solid malignancies and hepatitis B surface antigen-positive hepatitis B underwent cytotoxic chemotherapy with steroids. They were followed up for at least 6 months after the completion of chemotherapy. The chemotherapeutic regimens comprised carboplatin and paclitaxel for non-small-cell lung cancer, and docetaxel monotherapy or cyclophosphamide plus epirubicin for breast cancer, respectively. All patients completed chemotherapy with steroids without developing severe hepatitis that could be attributable to HBV reactivation. Entecavir prevented the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy for malignancies. Although further studies are required to evaluate whether entecavir can prevent the increased risk of YMDD mutation and decrease the rates of disrupted chemotherapy due to severe hepatitis more effectively than lamivudine, entecavir should be considered before lamivudine for such patients. More... »

PAGES

214-217

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12328-009-0063-2

DOI

http://dx.doi.org/10.1007/s12328-009-0063-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1046889229

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26192299


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
            "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okita", 
        "givenName": "Riki", 
        "id": "sg:person.0762510547.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762510547.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Surgery, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
            "Department of Breast Surgery, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Takahashi", 
        "givenName": "Mamoru", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narahara", 
        "givenName": "Hiroyuki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sanada", 
        "givenName": "Yuichi", 
        "id": "sg:person.01105006711.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105006711.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okada", 
        "givenName": "Morihito", 
        "id": "sg:person.011472205332.34", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011472205332.34"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kawakami", 
        "givenName": "Yoshiiku", 
        "id": "sg:person.01367420204.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367420204.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan", 
          "id": "http://www.grid.ac/institutes/grid.470097.d", 
          "name": [
            "Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chayama", 
        "givenName": "Kazuaki", 
        "id": "sg:person.01277325545.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277325545.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Gastroenterology, Shimonoseki Kosei Hospital, Kamishinchi-cho 3-3-8, 750-0061, Shimonoseki, Yamaguchi, Japan", 
          "id": "http://www.grid.ac/institutes/None", 
          "name": [
            "Department of Gastroenterology, Shimonoseki Kosei Hospital, Kamishinchi-cho 3-3-8, 750-0061, Shimonoseki, Yamaguchi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Okita", 
        "givenName": "Kiwamu", 
        "id": "sg:person.01334252105.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334252105.61"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10549-004-0725-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005128696", 
          "https://doi.org/10.1007/s10549-004-0725-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-02-21", 
    "datePublishedReg": "2009-02-21", 
    "description": "Reactivation of hepatitis B virus (HBV) infection is a frequent complication of cytotoxic chemotherapy that includes steroids. International studies have shown that lamivudine reduces the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy to treat malignancies. However, prolonged lamivudine therapy is associated with an increased risk of drug-resistant tyrosine-methionine-aspartate-aspartate (YMDD) mutations. Here, we studied the role of entecavir in preventing morbidity and mortality associated with HBV reactivation. Three patients with both solid malignancies and hepatitis B surface antigen-positive hepatitis B underwent cytotoxic chemotherapy with steroids. They were followed up for at least 6\u00a0months after the completion of chemotherapy. The chemotherapeutic regimens comprised carboplatin and paclitaxel for non-small-cell lung cancer, and docetaxel monotherapy or cyclophosphamide plus epirubicin for breast cancer, respectively. All patients completed chemotherapy with steroids without developing severe hepatitis that could be attributable to HBV reactivation. Entecavir prevented the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy for malignancies. Although further studies are required to evaluate whether entecavir can prevent the increased risk of YMDD mutation and decrease the rates of disrupted chemotherapy due to severe hepatitis more effectively than lamivudine, entecavir should be considered before lamivudine for such patients.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s12328-009-0063-2", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1040188", 
        "issn": [
          "1865-7257", 
          "1865-7265"
        ], 
        "name": "Clinical Journal of Gastroenterology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "2"
      }
    ], 
    "keywords": [
      "severity of hepatitis", 
      "cytotoxic chemotherapy", 
      "HBV reactivation", 
      "HBV carriers", 
      "severe hepatitis", 
      "solid malignancies", 
      "hepatitis B virus reactivation", 
      "hepatitis B virus infection", 
      "aspartate-aspartate (YMDD) mutations", 
      "role of entecavir", 
      "use of entecavir", 
      "B virus reactivation", 
      "completion of chemotherapy", 
      "B virus infection", 
      "cell lung cancer", 
      "lamivudine therapy", 
      "docetaxel monotherapy", 
      "YMDD mutations", 
      "frequent complication", 
      "hepatitis B", 
      "virus reactivation", 
      "such patients", 
      "chemotherapeutic regimens", 
      "lung cancer", 
      "virus infection", 
      "breast cancer", 
      "entecavir", 
      "chemotherapy", 
      "hepatitis", 
      "malignancy", 
      "lamivudine", 
      "patients", 
      "steroids", 
      "Further studies", 
      "cancer", 
      "incidence", 
      "international studies", 
      "severity", 
      "reactivation", 
      "risk", 
      "monotherapy", 
      "cyclophosphamide", 
      "morbidity", 
      "regimens", 
      "complications", 
      "carboplatin", 
      "epirubicin", 
      "therapy", 
      "infection", 
      "mortality", 
      "mutations", 
      "paclitaxel", 
      "months", 
      "study", 
      "completion", 
      "carriers", 
      "role", 
      "rate", 
      "use"
    ], 
    "name": "Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy", 
    "pagination": "214-217", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1046889229"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12328-009-0063-2"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26192299"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12328-009-0063-2", 
      "https://app.dimensions.ai/details/publication/pub.1046889229"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_478.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s12328-009-0063-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12328-009-0063-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12328-009-0063-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12328-009-0063-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12328-009-0063-2'


 

This table displays all metadata directly associated to this object as RDF triples.

184 TRIPLES      21 PREDICATES      86 URIs      76 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12328-009-0063-2 schema:about anzsrc-for:11
2 anzsrc-for:1103
3 anzsrc-for:1112
4 schema:author N223c2d994b9c4375861a7ed4dd76a6dc
5 schema:citation sg:pub.10.1007/s10549-004-0725-1
6 schema:datePublished 2009-02-21
7 schema:datePublishedReg 2009-02-21
8 schema:description Reactivation of hepatitis B virus (HBV) infection is a frequent complication of cytotoxic chemotherapy that includes steroids. International studies have shown that lamivudine reduces the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy to treat malignancies. However, prolonged lamivudine therapy is associated with an increased risk of drug-resistant tyrosine-methionine-aspartate-aspartate (YMDD) mutations. Here, we studied the role of entecavir in preventing morbidity and mortality associated with HBV reactivation. Three patients with both solid malignancies and hepatitis B surface antigen-positive hepatitis B underwent cytotoxic chemotherapy with steroids. They were followed up for at least 6 months after the completion of chemotherapy. The chemotherapeutic regimens comprised carboplatin and paclitaxel for non-small-cell lung cancer, and docetaxel monotherapy or cyclophosphamide plus epirubicin for breast cancer, respectively. All patients completed chemotherapy with steroids without developing severe hepatitis that could be attributable to HBV reactivation. Entecavir prevented the incidence and severity of hepatitis in HBV carriers undergoing chemotherapy for malignancies. Although further studies are required to evaluate whether entecavir can prevent the increased risk of YMDD mutation and decrease the rates of disrupted chemotherapy due to severe hepatitis more effectively than lamivudine, entecavir should be considered before lamivudine for such patients.
9 schema:genre article
10 schema:isAccessibleForFree false
11 schema:isPartOf Nbce01caf71b24a759ab1c1da2e45ea9c
12 Ncff46de81c8d47999d11884fcf20bc76
13 sg:journal.1040188
14 schema:keywords B virus infection
15 B virus reactivation
16 Further studies
17 HBV carriers
18 HBV reactivation
19 YMDD mutations
20 aspartate-aspartate (YMDD) mutations
21 breast cancer
22 cancer
23 carboplatin
24 carriers
25 cell lung cancer
26 chemotherapeutic regimens
27 chemotherapy
28 completion
29 completion of chemotherapy
30 complications
31 cyclophosphamide
32 cytotoxic chemotherapy
33 docetaxel monotherapy
34 entecavir
35 epirubicin
36 frequent complication
37 hepatitis
38 hepatitis B
39 hepatitis B virus infection
40 hepatitis B virus reactivation
41 incidence
42 infection
43 international studies
44 lamivudine
45 lamivudine therapy
46 lung cancer
47 malignancy
48 monotherapy
49 months
50 morbidity
51 mortality
52 mutations
53 paclitaxel
54 patients
55 rate
56 reactivation
57 regimens
58 risk
59 role
60 role of entecavir
61 severe hepatitis
62 severity
63 severity of hepatitis
64 solid malignancies
65 steroids
66 study
67 such patients
68 therapy
69 use
70 use of entecavir
71 virus infection
72 virus reactivation
73 schema:name Use of entecavir to prevent hepatitis B virus reactivation during cytotoxic chemotherapy for solid malignancy
74 schema:pagination 214-217
75 schema:productId N02dcbd7c6f954cd39082e4e958ab92e9
76 N21faa8fce8d4478981f1c81f07b55efb
77 N6ad33806185042ad8fc8e0d142ba1301
78 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046889229
79 https://doi.org/10.1007/s12328-009-0063-2
80 schema:sdDatePublished 2022-12-01T06:27
81 schema:sdLicense https://scigraph.springernature.com/explorer/license/
82 schema:sdPublisher Need8295f38d8497baace2d674d85de63
83 schema:url https://doi.org/10.1007/s12328-009-0063-2
84 sgo:license sg:explorer/license/
85 sgo:sdDataset articles
86 rdf:type schema:ScholarlyArticle
87 N02dcbd7c6f954cd39082e4e958ab92e9 schema:name dimensions_id
88 schema:value pub.1046889229
89 rdf:type schema:PropertyValue
90 N21faa8fce8d4478981f1c81f07b55efb schema:name pubmed_id
91 schema:value 26192299
92 rdf:type schema:PropertyValue
93 N223c2d994b9c4375861a7ed4dd76a6dc rdf:first sg:person.0762510547.74
94 rdf:rest Ne96d186d4451442fba77feb404bc57ba
95 N63f76f39e583402587f39e1844cf6041 rdf:first sg:person.01367420204.63
96 rdf:rest N72b29022bf1b430d9738f8c4d386e830
97 N692dc88e1ca4424e850a466bafd9905d schema:affiliation grid-institutes:grid.470097.d
98 schema:familyName Narahara
99 schema:givenName Hiroyuki
100 rdf:type schema:Person
101 N6ad33806185042ad8fc8e0d142ba1301 schema:name doi
102 schema:value 10.1007/s12328-009-0063-2
103 rdf:type schema:PropertyValue
104 N72b29022bf1b430d9738f8c4d386e830 rdf:first sg:person.01277325545.79
105 rdf:rest Nbc80caaf302f47649b44a42182805ad4
106 N891f800cf0ef44588aab6e02b2e9d4bc schema:affiliation grid-institutes:grid.470097.d
107 schema:familyName Takahashi
108 schema:givenName Mamoru
109 rdf:type schema:Person
110 Nb47efead77cc42d590b8440690be1e94 rdf:first N692dc88e1ca4424e850a466bafd9905d
111 rdf:rest Ne3dd96b8cb4e4cf88c9db72b8536449b
112 Nbc80caaf302f47649b44a42182805ad4 rdf:first sg:person.01334252105.61
113 rdf:rest rdf:nil
114 Nbce01caf71b24a759ab1c1da2e45ea9c schema:issueNumber 3
115 rdf:type schema:PublicationIssue
116 Ncff46de81c8d47999d11884fcf20bc76 schema:volumeNumber 2
117 rdf:type schema:PublicationVolume
118 Ne3dd96b8cb4e4cf88c9db72b8536449b rdf:first sg:person.01105006711.43
119 rdf:rest Nf906229a69cb4a02a447170f46e15d43
120 Ne96d186d4451442fba77feb404bc57ba rdf:first N891f800cf0ef44588aab6e02b2e9d4bc
121 rdf:rest Nb47efead77cc42d590b8440690be1e94
122 Need8295f38d8497baace2d674d85de63 schema:name Springer Nature - SN SciGraph project
123 rdf:type schema:Organization
124 Nf906229a69cb4a02a447170f46e15d43 rdf:first sg:person.011472205332.34
125 rdf:rest N63f76f39e583402587f39e1844cf6041
126 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
127 schema:name Medical and Health Sciences
128 rdf:type schema:DefinedTerm
129 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
130 schema:name Clinical Sciences
131 rdf:type schema:DefinedTerm
132 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
133 schema:name Oncology and Carcinogenesis
134 rdf:type schema:DefinedTerm
135 sg:journal.1040188 schema:issn 1865-7257
136 1865-7265
137 schema:name Clinical Journal of Gastroenterology
138 schema:publisher Springer Nature
139 rdf:type schema:Periodical
140 sg:person.01105006711.43 schema:affiliation grid-institutes:grid.470097.d
141 schema:familyName Sanada
142 schema:givenName Yuichi
143 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01105006711.43
144 rdf:type schema:Person
145 sg:person.011472205332.34 schema:affiliation grid-institutes:grid.470097.d
146 schema:familyName Okada
147 schema:givenName Morihito
148 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011472205332.34
149 rdf:type schema:Person
150 sg:person.01277325545.79 schema:affiliation grid-institutes:grid.470097.d
151 schema:familyName Chayama
152 schema:givenName Kazuaki
153 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277325545.79
154 rdf:type schema:Person
155 sg:person.01334252105.61 schema:affiliation grid-institutes:None
156 schema:familyName Okita
157 schema:givenName Kiwamu
158 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334252105.61
159 rdf:type schema:Person
160 sg:person.01367420204.63 schema:affiliation grid-institutes:grid.470097.d
161 schema:familyName Kawakami
162 schema:givenName Yoshiiku
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367420204.63
164 rdf:type schema:Person
165 sg:person.0762510547.74 schema:affiliation grid-institutes:grid.470097.d
166 schema:familyName Okita
167 schema:givenName Riki
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0762510547.74
169 rdf:type schema:Person
170 sg:pub.10.1007/s10549-004-0725-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005128696
171 https://doi.org/10.1007/s10549-004-0725-1
172 rdf:type schema:CreativeWork
173 grid-institutes:None schema:alternateName Department of Gastroenterology, Shimonoseki Kosei Hospital, Kamishinchi-cho 3-3-8, 750-0061, Shimonoseki, Yamaguchi, Japan
174 schema:name Department of Gastroenterology, Shimonoseki Kosei Hospital, Kamishinchi-cho 3-3-8, 750-0061, Shimonoseki, Yamaguchi, Japan
175 rdf:type schema:Organization
176 grid-institutes:grid.470097.d schema:alternateName Department of Breast Surgery, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
177 Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
178 Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
179 Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
180 schema:name Department of Breast Surgery, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
181 Department of Clinical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
182 Department of Medicine and Molecular Science, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
183 Department of Surgical Oncology, Hiroshima University Hospital, Kasumi 1-2-3, Minami-ku, 734-8553, Hiroshima, Japan
184 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...